Search

Displaying results 461 - 470 of 4591 in total
  1. Drug

    Miglitol

    go.drugbank.com/drugs/DB00491
    Approved

    monosaccharides which can be absorbed by the body. … Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys.

  2. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.

  3. Drug

    Aminophenazone

    go.drugbank.com/drugs/DB01424
    ApprovedWithdrawn

    Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to ...

  4. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    years and older with a body weight of at least 40 kg. … [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]

  5. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. … [A242372] The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with

  6. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH

  7. Drug

    Panthenol

    go.drugbank.com/drugs/DB11204
    Approved

    Panthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Panthenol exists as a racemic mixture containing both the dextrorotatory form ...

    Mixtures: Zaol Doctors Order Scalp Scaling, Zaol Doctors Order Synergy Booster
  8. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    It was first approved by the FDA in 2017. … [A180478] Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.

  9. Drug

    Warfarin

    go.drugbank.com/drugs/DB00682
    ApprovedInvestigational

    Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

    Categories: Vitamin K Inhibitors, Vitamin K Antagonists
  10. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    and 5 years and older respectively. … [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.